{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:36:04Z","timestamp":1783474564098,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clon.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T20:16:10Z","timestamp":1617653770000},"page":"483-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?"],"prefix":"10.1016","volume":"33","author":[{"given":"M.S.","family":"Andres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clon.2021.03.012_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: a common contributor to cancer, aging, and cardiovascular diseases\u2014expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clon.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","article-title":"Early anthracycline cardiotoxicity","volume":"65","author":"Bristow","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.clon.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11936-019-0733-4","article-title":"Cardio-oncology fellowship training and education","volume":"21","author":"Fradley","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.clon.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2021.03.012_bib11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ejhf.1336","article-title":"How to build a cardio-oncology service?","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40959-016-0014-2","article-title":"Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic","volume":"2","author":"Barros-Gomes","year":"2016","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.clon.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12872-020-01471-8","article-title":"Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo","volume":"20","author":"Costa IBS da","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clon.2021.03.012_bib15","first-page":"340","article-title":"Developing a comprehensive cardio-oncology program at a cancer institute: the Moffitt Cancer Center Experience","volume":"11","author":"Fradley","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.clon.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijcard.2020.06.003","article-title":"Cardio-oncology \u2013 more than just cardiac complications of cancer treatment","volume":"317","author":"Ghosh","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/ehf2.12840","article-title":"The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan","volume":"7","author":"Chang","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/eurheartj\/ehz935","article-title":"Cardiology care delivered to cancer patients","volume":"41","author":"Asteggiano","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","article-title":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","volume":"65","author":"Barac","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40959-019-0049-2","article-title":"An international survey of healthcare providers\u2019 knowledge of cardiac complications of cancer treatments","volume":"5","author":"Peng","year":"2019","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.clon.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12885-016-2761-8","article-title":"Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)","volume":"16","author":"Pituskin","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3747\/co.26.4509","article-title":"Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study","volume":"26","author":"Kappel","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jacc.2016.01.018","article-title":"Provision and clinical utility of cardio-oncology services for detection of cardiac toxicity in cancer patients","volume":"67","author":"Gujral","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jaccao.2019.10.003","article-title":"Cardio-oncology and the intersection of cancer and cardiotoxicity","volume":"1","author":"Cheng","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clon.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.hfc.2016.12.012","article-title":"How to develop a cardio-oncology fellowship","volume":"13","author":"Johnson","year":"2017","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.clon.2021.03.012_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cardfail.2016.03.012","article-title":"Cardio-oncology training: a proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty","volume":"22","author":"Lenihan","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12265-020-10010-x","article-title":"Clinical practice and research in cardio-oncology: finding the \u201cRosetta Stone\u201d for establishing program excellence in cardio-oncology","volume":"13","author":"Adusumalli","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.clon.2021.03.012_bib33","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/eurheartj\/ehaa641","article-title":"ESC core curriculum for the cardiologist","volume":"41","author":"Tanner","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib34","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A\u00a0population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib35","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib36","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clon.2021.03.012_bib37","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.03.012_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005294","article-title":"Cardioprotection during therapeutic radiation treatment: peeling the onion of radiation cardiotoxicity?","volume":"11","author":"Lenihan","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.clon.2015.06.007","article-title":"Cardiac side-effects from breast cancer radiotherapy","volume":"27","author":"Taylor","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2021.03.012_bib42","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl.2","key":"10.1016\/j.clon.2021.03.012_bib44","first-page":"ehaa946","article-title":"Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 1 year results of the SUCCOUR trial","volume":"41","author":"Negishi","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.clon.2021.03.012_bib47","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib48","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.clon.2021.03.012_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.currproblcancer.2018.06.012","article-title":"The role of cardiac biomarkers in Cardio-Oncology","volume":"42","author":"Riddell","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clon.2021.03.012_bib51","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/0192623310382438","article-title":"Troponin as a biomarker of cardiac toxicity: past, present, and future","volume":"38","author":"Reagan","year":"2010","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.clon.2021.03.012_bib52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clon.2021.03.012_bib53","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamacardio.2019.2724","article-title":"Myocardial injury in the era of high-sensitivity cardiac troponin assays: a practical approach for clinicians","volume":"4","author":"McCarthy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","article-title":"Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy","volume":"32","author":"Tzolos","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib55","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clon.2021.03.012_bib56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib57","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib58","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib59","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management\u2014part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib60","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies \u2013 focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J\u00a0Am Soc Hypertens JASH"},{"key":"10.1016\/j.clon.2021.03.012_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy - a systematic review","volume":"323","author":"Lobenwein","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib63","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.03.012_bib64","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clon.2021.03.012_bib65","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib66","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clon.2021.03.012_bib67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrcardio.2017.47","article-title":"Pathology, imaging, and treatment of cardiac tumours","volume":"14","author":"Maleszewski","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib68","first-page":"855","article-title":"Benign cardiac tumours associated with sudden death","volume":"16","author":"Patel","year":"2014","journal-title":"EP Eur"},{"key":"10.1016\/j.clon.2021.03.012_bib69","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib70","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/heartjnl-2017-311261","article-title":"Carcinoid heart disease","volume":"103","author":"Hassan","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.clon.2021.03.012_bib71","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","article-title":"Radiation-induced valvular heart disease","volume":"102","author":"Gujral","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.clon.2021.03.012_bib72","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clon.2021.03.012_bib73","first-page":"1810","article-title":"Oncology and cardiac rehabilitation: an underrated relationship","volume":"9","author":"Venturini","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.clon.2021.03.012_bib74","first-page":"559","article-title":"Cardio-oncology rehabilitation \u2013 challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors","volume":"76","author":"Sase","year":"2020","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.clon.2021.03.012_bib75","article-title":"Cardio-oncology at the beginning of a new decade","volume":"9","author":"Grumbach","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clon.2021.03.012_bib76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaccao.2019.08.007","article-title":"The evolving design of NIH-funded cardio-oncology studies to address cancer treatment-related cardiovascular toxicity","volume":"1","author":"Minasian","year":"2019","journal-title":"JACC CardioOncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:11Z","timestamp":1760543351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655521001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0936655521001035"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2021.03.012","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}